Background and objective Targeted therapy in non-small cell lung cancer (NSCLC) had
become a research hotspot. Both of gefitinib and erlotinib had already been recommended …

Objective To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of
patients with advanced EGFR mutation-positive NSCLC. Methods Fifty patients with …

Objective: The objective of this study was to compare the efficacies of gefitinib and erlotinib
in treating EGFR-mutated non-small-cell lung cancer (NSCLC) patients. Methods: 319 EGFR …

Background: The phase II NEJ001 trial suggested that gefitinib was active against advanced
non-small cell lung cancer (NSCLC) even in patients with poor performance status (PS) …

7571 Background: NEJ002, a phase III trial comparing gefitinib with carboplatin-paclitaxel as
the first-line treatment for advanced NSCLC with sensitive EGFR mutations, showed a …

Gefitinib is effective in treating advanced non-small cell lung cancer (NSCLC), especially in
Asian patients in whom the prevalence of epidermal growth factor receptor (EGFR) mutation …

Background Several clinical trials showed that erlotinib was effective after the failure of
gefitinib in advanced non-small cell lung cancer (NSCLC). The aim of this study was to …

Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …

Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …

Background: Gefitinib treatment has come to be recognized as the standard therapy for
patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …